Although our data suggest that KIAA1199 is a potential biomarker for pancreatic cancer, further study is needed to assess the sensitivity and specificity of KIAA1199 autoantibody in PanIN patient serum for early diagnosis. This evidence concerns the gene CEMIP and familial pancreatic carcinoma.